Human Recombinant IL-2 Augments Immunoglobulin and Induces Rheumatoid Factor Production by Rheumatoid Arthritis Lymphocytes Engrafted into Severe Combined Immunodeficient Mice

Rashmi Kaul, Arun Sharma, Jeffrey R. Lisse, Premkumar Christadoss

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recombinant (r) human IL-2 was administered in vivo to improve homing and engraftment of rheumatoid arthritis (RA) patients' peripheral blood mononuclear cells (PBMC) into severe combined immunodeficient (SCID) mice. Human rIL-2 treatment resulted in augmented human Ig production and induced IgM rheumatoid factor (RF) of human origin in SCID-RA chimeras. The increment of human serum IgG in SCID-RA chimeras after IL-2 treatment ranged between 15 and 43% and for IgM between 50 and 98% during 2-8 weeks postengraftment. Human IgM-RF was detectable after 1 to 2 weeks after engraftment and persisted over a period of 10-13 weeks. No RF was produced in SCID mice engrafted with PBMC from healthy individuals with or without exogenous rIL-2 administration. Thus, human rIL-2 expanded autoreactive clones involved in the production of RF in the SCIDRA chimeras. The present study provides a novel approach to establish an in vivo SCID-RA model to study the cellular and molecular mechanisms involved in the production of RF and development of a RA-like lesion.

Original languageEnglish (US)
Pages (from-to)271-282
Number of pages12
JournalClinical Immunology and Immunopathology
Volume74
Issue number3
DOIs
StatePublished - Mar 1995

Fingerprint

SCID Mice
Rheumatoid Factor
Interleukin-2
Immunoglobulins
Rheumatoid Arthritis
Lymphocytes
Immunoglobulin M
Blood Cells
Clone Cells
Immunoglobulin G
Therapeutics
Serum

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Immunology and Allergy
  • Immunology

Cite this

Human Recombinant IL-2 Augments Immunoglobulin and Induces Rheumatoid Factor Production by Rheumatoid Arthritis Lymphocytes Engrafted into Severe Combined Immunodeficient Mice. / Kaul, Rashmi; Sharma, Arun; Lisse, Jeffrey R.; Christadoss, Premkumar.

In: Clinical Immunology and Immunopathology, Vol. 74, No. 3, 03.1995, p. 271-282.

Research output: Contribution to journalArticle

@article{cfc8bc39ac4045b182b61ef4b2bab3eb,
title = "Human Recombinant IL-2 Augments Immunoglobulin and Induces Rheumatoid Factor Production by Rheumatoid Arthritis Lymphocytes Engrafted into Severe Combined Immunodeficient Mice",
abstract = "Recombinant (r) human IL-2 was administered in vivo to improve homing and engraftment of rheumatoid arthritis (RA) patients' peripheral blood mononuclear cells (PBMC) into severe combined immunodeficient (SCID) mice. Human rIL-2 treatment resulted in augmented human Ig production and induced IgM rheumatoid factor (RF) of human origin in SCID-RA chimeras. The increment of human serum IgG in SCID-RA chimeras after IL-2 treatment ranged between 15 and 43{\%} and for IgM between 50 and 98{\%} during 2-8 weeks postengraftment. Human IgM-RF was detectable after 1 to 2 weeks after engraftment and persisted over a period of 10-13 weeks. No RF was produced in SCID mice engrafted with PBMC from healthy individuals with or without exogenous rIL-2 administration. Thus, human rIL-2 expanded autoreactive clones involved in the production of RF in the SCIDRA chimeras. The present study provides a novel approach to establish an in vivo SCID-RA model to study the cellular and molecular mechanisms involved in the production of RF and development of a RA-like lesion.",
author = "Rashmi Kaul and Arun Sharma and Lisse, {Jeffrey R.} and Premkumar Christadoss",
year = "1995",
month = "3",
doi = "10.1006/clin.1995.1039",
language = "English (US)",
volume = "74",
pages = "271--282",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Human Recombinant IL-2 Augments Immunoglobulin and Induces Rheumatoid Factor Production by Rheumatoid Arthritis Lymphocytes Engrafted into Severe Combined Immunodeficient Mice

AU - Kaul, Rashmi

AU - Sharma, Arun

AU - Lisse, Jeffrey R.

AU - Christadoss, Premkumar

PY - 1995/3

Y1 - 1995/3

N2 - Recombinant (r) human IL-2 was administered in vivo to improve homing and engraftment of rheumatoid arthritis (RA) patients' peripheral blood mononuclear cells (PBMC) into severe combined immunodeficient (SCID) mice. Human rIL-2 treatment resulted in augmented human Ig production and induced IgM rheumatoid factor (RF) of human origin in SCID-RA chimeras. The increment of human serum IgG in SCID-RA chimeras after IL-2 treatment ranged between 15 and 43% and for IgM between 50 and 98% during 2-8 weeks postengraftment. Human IgM-RF was detectable after 1 to 2 weeks after engraftment and persisted over a period of 10-13 weeks. No RF was produced in SCID mice engrafted with PBMC from healthy individuals with or without exogenous rIL-2 administration. Thus, human rIL-2 expanded autoreactive clones involved in the production of RF in the SCIDRA chimeras. The present study provides a novel approach to establish an in vivo SCID-RA model to study the cellular and molecular mechanisms involved in the production of RF and development of a RA-like lesion.

AB - Recombinant (r) human IL-2 was administered in vivo to improve homing and engraftment of rheumatoid arthritis (RA) patients' peripheral blood mononuclear cells (PBMC) into severe combined immunodeficient (SCID) mice. Human rIL-2 treatment resulted in augmented human Ig production and induced IgM rheumatoid factor (RF) of human origin in SCID-RA chimeras. The increment of human serum IgG in SCID-RA chimeras after IL-2 treatment ranged between 15 and 43% and for IgM between 50 and 98% during 2-8 weeks postengraftment. Human IgM-RF was detectable after 1 to 2 weeks after engraftment and persisted over a period of 10-13 weeks. No RF was produced in SCID mice engrafted with PBMC from healthy individuals with or without exogenous rIL-2 administration. Thus, human rIL-2 expanded autoreactive clones involved in the production of RF in the SCIDRA chimeras. The present study provides a novel approach to establish an in vivo SCID-RA model to study the cellular and molecular mechanisms involved in the production of RF and development of a RA-like lesion.

UR - http://www.scopus.com/inward/record.url?scp=0028925475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028925475&partnerID=8YFLogxK

U2 - 10.1006/clin.1995.1039

DO - 10.1006/clin.1995.1039

M3 - Article

C2 - 7859417

AN - SCOPUS:0028925475

VL - 74

SP - 271

EP - 282

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -